SCHEMBL24348209

SCHEMBL24348209

CCCOc1ccc(/C=N/Nc2nc3ccccc3[nH]2)c(OCCC)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 17/20 0.59
▸ GAA P10253 14/20 0.59
▸ KMT2A Q03164 11/20 0.58
▸ RAB9A P51151 9/20 0.58
▸ MEN1 O00255 8/20 0.58
▸ RECQL P46063 1/20 0.58
▸ NPC1 O15118 9/20 0.56
▸ TDP1 Q9NUW8 8/20 0.55
▸ KDM4E B2RXH2 7/20 0.55
▸ L3MBTL1 Q9Y468 4/20 0.55
▸ GFER P55789 3/20 0.55
▸ MAPK1 P28482 1/20 0.55
▸ HTT P42858 8/20 0.54
▸ KDM4C Q9H3R0 1/20 0.53
▸ SMN1; SMN2 Q16637 5/20 0.53
▸ NPSR1 Q6W5P4 5/20 0.53
▸ LMNA P02545 4/20 0.53
▸ POLB P06746 4/20 0.53
▸ HPGD P15428 2/20 0.53
▸ ALDH1A1 P00352 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14942678 0.76 MAPT (0.68) MAPTGAAKMT2ARAB9AMEN1
SCHEMBL10280285 0.72 MAPT (0.73) MAPTGAAKMT2ARAB9AMEN1
SCHEMBL11744247 0.71 MEN1 (0.53) MAPTKMT2ARAB9AMEN1NPC1
SCHEMBL880349 0.70 GAA (1.00) MAPTGAAKMT2ARAB9AMEN1
SCHEMBL5033211 0.69 MAPT (1.00) MAPTGAAKMT2ARAB9AMEN1
SCHEMBL5033202 0.69 MAPT (1.00) MAPTGAAKMT2ARAB9AMEN1
SCHEMBL880212 0.69 PLA2G10 (0.72) MAPTGAAKMT2ARAB9AMEN1
SCHEMBL10280286 0.69 MAPT (1.00) MAPTGAAKMT2ARAB9AMEN1
SCHEMBL10280287 0.69 MAPT (0.76) MAPTGAAKMT2ARAB9AMEN1
SCHEMBL15359675 0.69 MAPT (0.76) MAPTGAAKMT2ARAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220105076-A1 Inhibitor for V-Atpase Activity, Antibacterial Agent, Medicine, Antibacterial Method and Screening Method JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2022-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220105076-A1 Inhibitor for V-Atpase Activity, Antibacterial Agent, Medicine, Antibacterial Method and Screening Method ATP6V1E1, ATP6V1G1, ATP6AP1 MAPT 4834/4885GAA 156/4885KMT2A 2668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback